Get this delivered to your inbox, and more info about our products and services.
It's a high-risk trade, but this biotech down 80% this year could be a buy
Jay Woods breaks down the charts on Sarepta.
14 words~1 min read
Related reading
This biotech stock could see a sharp swing higher after years of struggling,…
Chart analyst Frank Cappelleri breaks down the technical outlook on the biotech stock.
The charts are showing this biotech stock can strengthen into year-end
David Keller breaks down the technicals on this biotech giant.
There's a 'bearish-to-bullish' reversal happening in this biotech stock, says…
Carter Worth breaks down the charts on this biotech stock.
An under-the-radar medical device stock with 20% upside, according to the charts
Jay Woods breaks down the charts in Steris.
RBC sees nearly 30% upside for this medical tech stock as headwinds abate
The bank pointed to recent M&A success as a catalyst for the stock.
A potential 'home run' trade is emerging in this hot pharma stock
Tony Zhang breaks down how to trade this stock using options.